Herantis Pharma (Finland) Today
| HRTIS Stock | EUR 1.56 0.07 4.29% |
Performance4 of 100
| Odds Of DistressOver 75
|
Herantis Pharma is trading at 1.56 as of the 27th of December 2024. This is a 4.29 percent decrease since the beginning of the trading day. The stock's open price was 1.63. Herantis Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 27th of December 2024. Click here to learn more.
Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. The company was founded in 2008 and is based in Espoo, Finland. Herantis Pharma operates under Pharmaceuticals And Biosciences classification in Finland and is traded on Helsinki Exchange. The company has 16.91 M outstanding shares. More on Herantis Pharma Oyj
Moving against Herantis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Herantis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Herantis Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Herantis Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
Herantis Pharma Oyj (HRTIS) is traded on Helsinki Exchange in Finland and employs 13 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Herantis Pharma's market, we take the total number of its shares issued and multiply it by Herantis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Herantis Pharma Oyj operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 16.91 M outstanding shares.
Herantis Pharma Oyj has accumulated about 7.86 M in cash with (9.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Herantis Pharma Probability Of Bankruptcy
Ownership AllocationHerantis Pharma Oyj has a total of 16.91 Million outstanding shares. Herantis Pharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Herantis Ownership Details
Herantis Pharma Oyj Risk Profiles
Although Herantis Pharma's alpha and beta are two of the key measurements used to evaluate Herantis Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.03 | |||
| Semi Deviation | 2.1 | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.47 |
Herantis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Herantis Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Herantis Pharma Corporate Management
Elected by the shareholders, the Herantis Pharma's board of directors comprises two types of representatives: Herantis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Herantis. The board's role is to monitor Herantis Pharma's management team and ensure that shareholders' interests are well served. Herantis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Herantis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henri Huttunen | Chief Scientific Officer | Profile | |
| Antti D | CEO COO | Profile | |
| Jutta Poutanen | Chief Pharmaceutical Officer | Profile | |
| Jani Koskinen | Project Manager | Profile | |
| Outi MD | Chief Ofcer | Profile | |
| Tone Kvale | Chief Officer | Profile |
Other Information on Investing in Herantis Stock
Herantis Pharma financial ratios help investors to determine whether Herantis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Herantis with respect to the benefits of owning Herantis Pharma security.